Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, provides an outlook on the treatment of HER2-positive breast cancer.
The biggest shift in this space will be moving away from traditional chemotherapy. Research is planned, Verma says, to look at approaches that may consist of trastuzumab, lapatinib, pertuzumab, or T-DM1 alone, or T-DM1 in combination with pertuzumab.
Data in the metastatic setting suggest that a T-DM1-based combination may be most beneficial. Verma says that a future in which patients with HER2-positive breast cancer do not lose their hair and have no risk of infection would represent a huge achievement.
<<< View more from the 2014 Miami Breast Cancer Conference